Global Human Insulin Drugs and Delivery Devices Market by Drug (Insulin Analogs & Biosimilar, Premixed Biologics, Premixed Biosimilar, Short-Acting Biologics, Long-Acting Biosimilar, Human Insulin Biologics, Rapid-Acting Biosimilar, Intermediate-Acting Biologics), by Human Insulin (HI), by Delivery Device (Reusable Pens, Pens, Syringes, Safety Pen Needles, Pen Needles, Standard Pen Needles, Disposable Pens), by Product (Human Insulin (Human Insulin HI), by Application (Type II Diabetes, Type I Diabetes) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Up Market Research published a new report titled “Human Insulin Drugs and Delivery Devices Market research report which is segmented by Drug (Insulin Analogs & Biosimilar, Premixed Biologics, Premixed Biosimilar, Short-Acting Biologics, Long-Acting Biosimilar, Human Insulin Biologics, Rapid-Acting Biosimilar, Intermediate-Acting Biologics), by Human Insulin (HI), by Delivery Device (Reusable Pens, Pens, Syringes, Safety Pen Needles, Pen Needles, Standard Pen Needles, Disposable Pens), by Product (Human Insulin (Human Insulin HI), by Application (Type II Diabetes, Type I Diabetes), By Players/Companies Sanofi, AstraZeneca, WOCKHARDT, Johnson & Johnson Services Inc., B. Braun Melsungen AG, Eli Lilly and Company, Novartis AG, Biocon, BD, Novo Nordisk A/S, CeQur SA, Takeda Pharmaceutical Company Limited, Ypsomed, Merck & Co. Inc., BoehringerIngelheim International GmbH, Bayer AG, AlbireoPharma Inc., Julphar”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Human Insulin Drugs and Delivery Devices Market Research Report |
| By Drug | Insulin Analogs & Biosimilar, Premixed Biologics, Premixed Biosimilar, Short-Acting Biologics, Long-Acting Biosimilar, Human Insulin Biologics, Rapid-Acting Biosimilar, Intermediate-Acting Biologics |
| By Human Insulin | HI |
| By Delivery Device | Reusable Pens, Pens, Syringes, Safety Pen Needles, Pen Needles, Standard Pen Needles, Disposable Pens |
| By Product (Human Insulin | Human Insulin HI |
| By Application | Type II Diabetes, Type I Diabetes |
| By Companies | Sanofi, AstraZeneca, WOCKHARDT, Johnson & Johnson Services Inc., B. Braun Melsungen AG, Eli Lilly and Company, Novartis AG, Biocon, BD, Novo Nordisk A/S, CeQur SA, Takeda Pharmaceutical Company Limited, Ypsomed, Merck & Co. Inc., BoehringerIngelheim International GmbH, Bayer AG, AlbireoPharma Inc., Julphar |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 202 |
| Number of Tables & Figures | 142 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Human Insulin Drugs and Delivery Devices Market Report Segments:
The market is segmented by Drug (Insulin Analogs & Biosimilar, Premixed Biologics, Premixed Biosimilar, Short-Acting Biologics, Long-Acting Biosimilar, Human Insulin Biologics, Rapid-Acting Biosimilar, Intermediate-Acting Biologics), by Human Insulin (HI), by Delivery Device (Reusable Pens, Pens, Syringes, Safety Pen Needles, Pen Needles, Standard Pen Needles, Disposable Pens), by Product (Human Insulin (Human Insulin HI), by Application (Type II Diabetes, Type I Diabetes).
Some of the companies that are profiled in this report are:
- Sanofi
- AstraZeneca
- WOCKHARDT
- Johnson & Johnson Services Inc.
- B. Braun Melsungen AG
- Eli Lilly and Company
- Novartis AG
- Biocon
- BD
- Novo Nordisk A/S
- CeQur SA
- Takeda Pharmaceutical Company Limited
- Ypsomed
- Merck & Co. Inc.
- BoehringerIngelheim International GmbH
- Bayer AG
- AlbireoPharma Inc.
- Julphar
Human Insulin Drugs and Delivery Devices Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Human Insulin Drugs and Delivery Devices Market
Overview of the regional outlook of the Human Insulin Drugs and Delivery Devices Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Human Insulin Drugs and Delivery Devices Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Human Insulin Drugs and Delivery Devices Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Insulin Analogs & Biosimilar
2. Premixed Biologics
3. Premixed Biosimilar
4. Short-Acting Biologics
5. Long-Acting Biosimilar
6. Human Insulin Biologics
7. Rapid-Acting Biosimilar
8. Intermediate-Acting Biologics
7. By Human Insulin:1. HI
8. By Delivery Device:1. Reusable Pens
2. Pens
3. Syringes
4. Safety Pen Needles
5. Pen Needles
6. Standard Pen Needles
7. Disposable Pens
9. By Product (Human Insulin:1. Human Insulin HI
10. By Application:1. Type II Diabetes
2. Type I Diabetes
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Insulin Drugs and Delivery Devices Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Human Insulin Drugs and Delivery Devices Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Human Insulin Drugs and Delivery Devices Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Human Insulin Drugs and Delivery Devices Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Human Insulin Drugs and Delivery Devices Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Human Insulin Drugs and Delivery Devices Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Human Insulin Drugs and Delivery Devices Market Size & Forecast, 2018-2028
4.5.1 Human Insulin Drugs and Delivery Devices Market Size and Y-o-Y Growth
4.5.2 Human Insulin Drugs and Delivery Devices Market Absolute $ Opportunity
Chapter 5 Global Human Insulin Drugs and Delivery Devices Market Analysis and Forecast by Drug
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Drug
5.1.2 Basis Point Share (BPS) Analysis by Drug
5.1.3 Absolute $ Opportunity Assessment by Drug
5.2 Human Insulin Drugs and Delivery Devices Market Size Forecast by Drug
5.2.1 Insulin Analogs & Biosimilar
5.2.2 Premixed Biologics
5.2.3 Premixed Biosimilar
5.2.4 Short-Acting Biologics
5.2.5 Long-Acting Biosimilar
5.2.6 Human Insulin Biologics
5.2.7 Rapid-Acting Biosimilar
5.2.8 Intermediate-Acting Biologics
5.3 Market Attractiveness Analysis by Drug
Chapter 6 Global Human Insulin Drugs and Delivery Devices Market Analysis and Forecast by Human Insulin
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Human Insulin
6.1.2 Basis Point Share (BPS) Analysis by Human Insulin
6.1.3 Absolute $ Opportunity Assessment by Human Insulin
6.2 Human Insulin Drugs and Delivery Devices Market Size Forecast by Human Insulin
6.2.1 HI
6.3 Market Attractiveness Analysis by Human Insulin
Chapter 7 Global Human Insulin Drugs and Delivery Devices Market Analysis and Forecast by Delivery Device
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Delivery Device
7.1.2 Basis Point Share (BPS) Analysis by Delivery Device
7.1.3 Absolute $ Opportunity Assessment by Delivery Device
7.2 Human Insulin Drugs and Delivery Devices Market Size Forecast by Delivery Device
7.2.1 Reusable Pens
7.2.2 Pens
7.2.3 Syringes
7.2.4 Safety Pen Needles
7.2.5 Pen Needles
7.2.6 Standard Pen Needles
7.2.7 Disposable Pens
7.3 Market Attractiveness Analysis by Delivery Device
Chapter 8 Global Human Insulin Drugs and Delivery Devices Market Analysis and Forecast by Product (Human Insulin
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Product (Human Insulin
8.1.2 Basis Point Share (BPS) Analysis by Product (Human Insulin
8.1.3 Absolute $ Opportunity Assessment by Product (Human Insulin
8.2 Human Insulin Drugs and Delivery Devices Market Size Forecast by Product (Human Insulin
8.2.1 Human Insulin HI
8.3 Market Attractiveness Analysis by Product (Human Insulin
Chapter 9 Global Human Insulin Drugs and Delivery Devices Market Analysis and Forecast by Application
9.1 Introduction
9.1.1 Key Market Trends & Growth Opportunities by Application
9.1.2 Basis Point Share (BPS) Analysis by Application
9.1.3 Absolute $ Opportunity Assessment by Application
9.2 Human Insulin Drugs and Delivery Devices Market Size Forecast by Application
9.2.1 Type II Diabetes
9.2.2 Type I Diabetes
9.3 Market Attractiveness Analysis by Application
Chapter 10 Global Human Insulin Drugs and Delivery Devices Market Analysis and Forecast by Region
10.1 Introduction
10.1.1 Key Market Trends & Growth Opportunities by Region
10.1.2 Basis Point Share (BPS) Analysis by Region
10.1.3 Absolute $ Opportunity Assessment by Region
10.2 Human Insulin Drugs and Delivery Devices Market Size Forecast by Region
10.2.1 North America
10.2.2 Europe
10.2.3 Asia Pacific
10.2.4 Latin America
10.2.5 Middle East & Africa (MEA)
10.3 Market Attractiveness Analysis by Region
Chapter 11 Coronavirus Disease (COVID-19) Impact
11.1 Introduction
11.2 Current & Future Impact Analysis
11.3 Economic Impact Analysis
11.4 Government Policies
11.5 Investment Scenario
Chapter 12 North America Human Insulin Drugs and Delivery Devices Analysis and Forecast
12.1 Introduction
12.2 North America Human Insulin Drugs and Delivery Devices Market Size Forecast by Country
12.2.1 U.S.
12.2.2 Canada
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 North America Human Insulin Drugs and Delivery Devices Market Size Forecast by Drug
12.6.1 Insulin Analogs & Biosimilar
12.6.2 Premixed Biologics
12.6.3 Premixed Biosimilar
12.6.4 Short-Acting Biologics
12.6.5 Long-Acting Biosimilar
12.6.6 Human Insulin Biologics
12.6.7 Rapid-Acting Biosimilar
12.6.8 Intermediate-Acting Biologics
12.7 Basis Point Share (BPS) Analysis by Drug
12.8 Absolute $ Opportunity Assessment by Drug
12.9 Market Attractiveness Analysis by Drug
12.10 North America Human Insulin Drugs and Delivery Devices Market Size Forecast by Human Insulin
12.10.1 HI
12.11 Basis Point Share (BPS) Analysis by Human Insulin
12.12 Absolute $ Opportunity Assessment by Human Insulin
12.13 Market Attractiveness Analysis by Human Insulin
12.14 North America Human Insulin Drugs and Delivery Devices Market Size Forecast by Delivery Device
12.14.1 Reusable Pens
12.14.2 Pens
12.14.3 Syringes
12.14.4 Safety Pen Needles
12.14.5 Pen Needles
12.14.6 Standard Pen Needles
12.14.7 Disposable Pens
12.15 Basis Point Share (BPS) Analysis by Delivery Device
12.16 Absolute $ Opportunity Assessment by Delivery Device
12.17 Market Attractiveness Analysis by Delivery Device
12.18 North America Human Insulin Drugs and Delivery Devices Market Size Forecast by Product (Human Insulin
12.18.1 Human Insulin HI
12.19 Basis Point Share (BPS) Analysis by Product (Human Insulin
12.20 Absolute $ Opportunity Assessment by Product (Human Insulin
12.21 Market Attractiveness Analysis by Product (Human Insulin
12.22 North America Human Insulin Drugs and Delivery Devices Market Size Forecast by Application
12.22.1 Type II Diabetes
12.22.2 Type I Diabetes
12.23 Basis Point Share (BPS) Analysis by Application
12.24 Absolute $ Opportunity Assessment by Application
12.25 Market Attractiveness Analysis by Application
Chapter 13 Europe Human Insulin Drugs and Delivery Devices Analysis and Forecast
13.1 Introduction
13.2 Europe Human Insulin Drugs and Delivery Devices Market Size Forecast by Country
13.2.1 Germany
13.2.2 France
13.2.3 Italy
13.2.4 U.K.
13.2.5 Spain
13.2.6 Russia
13.2.7 Rest of Europe
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Europe Human Insulin Drugs and Delivery Devices Market Size Forecast by Drug
13.6.1 Insulin Analogs & Biosimilar
13.6.2 Premixed Biologics
13.6.3 Premixed Biosimilar
13.6.4 Short-Acting Biologics
13.6.5 Long-Acting Biosimilar
13.6.6 Human Insulin Biologics
13.6.7 Rapid-Acting Biosimilar
13.6.8 Intermediate-Acting Biologics
13.7 Basis Point Share (BPS) Analysis by Drug
13.8 Absolute $ Opportunity Assessment by Drug
13.9 Market Attractiveness Analysis by Drug
13.10 Europe Human Insulin Drugs and Delivery Devices Market Size Forecast by Human Insulin
13.10.1 HI
13.11 Basis Point Share (BPS) Analysis by Human Insulin
13.12 Absolute $ Opportunity Assessment by Human Insulin
13.13 Market Attractiveness Analysis by Human Insulin
13.14 Europe Human Insulin Drugs and Delivery Devices Market Size Forecast by Delivery Device
13.14.1 Reusable Pens
13.14.2 Pens
13.14.3 Syringes
13.14.4 Safety Pen Needles
13.14.5 Pen Needles
13.14.6 Standard Pen Needles
13.14.7 Disposable Pens
13.15 Basis Point Share (BPS) Analysis by Delivery Device
13.16 Absolute $ Opportunity Assessment by Delivery Device
13.17 Market Attractiveness Analysis by Delivery Device
13.18 Europe Human Insulin Drugs and Delivery Devices Market Size Forecast by Product (Human Insulin
13.18.1 Human Insulin HI
13.19 Basis Point Share (BPS) Analysis by Product (Human Insulin
13.20 Absolute $ Opportunity Assessment by Product (Human Insulin
13.21 Market Attractiveness Analysis by Product (Human Insulin
13.22 Europe Human Insulin Drugs and Delivery Devices Market Size Forecast by Application
13.22.1 Type II Diabetes
13.22.2 Type I Diabetes
13.23 Basis Point Share (BPS) Analysis by Application
13.24 Absolute $ Opportunity Assessment by Application
13.25 Market Attractiveness Analysis by Application
Chapter 14 Asia Pacific Human Insulin Drugs and Delivery Devices Analysis and Forecast
14.1 Introduction
14.2 Asia Pacific Human Insulin Drugs and Delivery Devices Market Size Forecast by Country
14.2.1 China
14.2.2 Japan
14.2.3 South Korea
14.2.4 India
14.2.5 Australia
14.2.6 South East Asia (SEA)
14.2.7 Rest of Asia Pacific (APAC)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Asia Pacific Human Insulin Drugs and Delivery Devices Market Size Forecast by Drug
14.6.1 Insulin Analogs & Biosimilar
14.6.2 Premixed Biologics
14.6.3 Premixed Biosimilar
14.6.4 Short-Acting Biologics
14.6.5 Long-Acting Biosimilar
14.6.6 Human Insulin Biologics
14.6.7 Rapid-Acting Biosimilar
14.6.8 Intermediate-Acting Biologics
14.7 Basis Point Share (BPS) Analysis by Drug
14.8 Absolute $ Opportunity Assessment by Drug
14.9 Market Attractiveness Analysis by Drug
14.10 Asia Pacific Human Insulin Drugs and Delivery Devices Market Size Forecast by Human Insulin
14.10.1 HI
14.11 Basis Point Share (BPS) Analysis by Human Insulin
14.12 Absolute $ Opportunity Assessment by Human Insulin
14.13 Market Attractiveness Analysis by Human Insulin
14.14 Asia Pacific Human Insulin Drugs and Delivery Devices Market Size Forecast by Delivery Device
14.14.1 Reusable Pens
14.14.2 Pens
14.14.3 Syringes
14.14.4 Safety Pen Needles
14.14.5 Pen Needles
14.14.6 Standard Pen Needles
14.14.7 Disposable Pens
14.15 Basis Point Share (BPS) Analysis by Delivery Device
14.16 Absolute $ Opportunity Assessment by Delivery Device
14.17 Market Attractiveness Analysis by Delivery Device
14.18 Asia Pacific Human Insulin Drugs and Delivery Devices Market Size Forecast by Product (Human Insulin
14.18.1 Human Insulin HI
14.19 Basis Point Share (BPS) Analysis by Product (Human Insulin
14.20 Absolute $ Opportunity Assessment by Product (Human Insulin
14.21 Market Attractiveness Analysis by Product (Human Insulin
14.22 Asia Pacific Human Insulin Drugs and Delivery Devices Market Size Forecast by Application
14.22.1 Type II Diabetes
14.22.2 Type I Diabetes
14.23 Basis Point Share (BPS) Analysis by Application
14.24 Absolute $ Opportunity Assessment by Application
14.25 Market Attractiveness Analysis by Application
Chapter 15 Latin America Human Insulin Drugs and Delivery Devices Analysis and Forecast
15.1 Introduction
15.2 Latin America Human Insulin Drugs and Delivery Devices Market Size Forecast by Country
15.2.1 Brazil
15.2.2 Mexico
15.2.3 Rest of Latin America (LATAM)
15.3 Basis Point Share (BPS) Analysis by Country
15.4 Absolute $ Opportunity Assessment by Country
15.5 Market Attractiveness Analysis by Country
15.6 Latin America Human Insulin Drugs and Delivery Devices Market Size Forecast by Drug
15.6.1 Insulin Analogs & Biosimilar
15.6.2 Premixed Biologics
15.6.3 Premixed Biosimilar
15.6.4 Short-Acting Biologics
15.6.5 Long-Acting Biosimilar
15.6.6 Human Insulin Biologics
15.6.7 Rapid-Acting Biosimilar
15.6.8 Intermediate-Acting Biologics
15.7 Basis Point Share (BPS) Analysis by Drug
15.8 Absolute $ Opportunity Assessment by Drug
15.9 Market Attractiveness Analysis by Drug
15.10 Latin America Human Insulin Drugs and Delivery Devices Market Size Forecast by Human Insulin
15.10.1 HI
15.11 Basis Point Share (BPS) Analysis by Human Insulin
15.12 Absolute $ Opportunity Assessment by Human Insulin
15.13 Market Attractiveness Analysis by Human Insulin
15.14 Latin America Human Insulin Drugs and Delivery Devices Market Size Forecast by Delivery Device
15.14.1 Reusable Pens
15.14.2 Pens
15.14.3 Syringes
15.14.4 Safety Pen Needles
15.14.5 Pen Needles
15.14.6 Standard Pen Needles
15.14.7 Disposable Pens
15.15 Basis Point Share (BPS) Analysis by Delivery Device
15.16 Absolute $ Opportunity Assessment by Delivery Device
15.17 Market Attractiveness Analysis by Delivery Device
15.18 Latin America Human Insulin Drugs and Delivery Devices Market Size Forecast by Product (Human Insulin
15.18.1 Human Insulin HI
15.19 Basis Point Share (BPS) Analysis by Product (Human Insulin
15.20 Absolute $ Opportunity Assessment by Product (Human Insulin
15.21 Market Attractiveness Analysis by Product (Human Insulin
15.22 Latin America Human Insulin Drugs and Delivery Devices Market Size Forecast by Application
15.22.1 Type II Diabetes
15.22.2 Type I Diabetes
15.23 Basis Point Share (BPS) Analysis by Application
15.24 Absolute $ Opportunity Assessment by Application
15.25 Market Attractiveness Analysis by Application
Chapter 16 Middle East & Africa (MEA) Human Insulin Drugs and Delivery Devices Analysis and Forecast
16.1 Introduction
16.2 Middle East & Africa (MEA) Human Insulin Drugs and Delivery Devices Market Size Forecast by Country
16.2.1 Saudi Arabia
16.2.2 South Africa
16.2.3 UAE
16.2.4 Rest of Middle East & Africa (MEA)
16.3 Basis Point Share (BPS) Analysis by Country
16.4 Absolute $ Opportunity Assessment by Country
16.5 Market Attractiveness Analysis by Country
16.6 Middle East & Africa (MEA) Human Insulin Drugs and Delivery Devices Market Size Forecast by Drug
16.6.1 Insulin Analogs & Biosimilar
16.6.2 Premixed Biologics
16.6.3 Premixed Biosimilar
16.6.4 Short-Acting Biologics
16.6.5 Long-Acting Biosimilar
16.6.6 Human Insulin Biologics
16.6.7 Rapid-Acting Biosimilar
16.6.8 Intermediate-Acting Biologics
16.7 Basis Point Share (BPS) Analysis by Drug
16.8 Absolute $ Opportunity Assessment by Drug
16.9 Market Attractiveness Analysis by Drug
16.10 Middle East & Africa (MEA) Human Insulin Drugs and Delivery Devices Market Size Forecast by Human Insulin
16.10.1 HI
16.11 Basis Point Share (BPS) Analysis by Human Insulin
16.12 Absolute $ Opportunity Assessment by Human Insulin
16.13 Market Attractiveness Analysis by Human Insulin
16.14 Middle East & Africa (MEA) Human Insulin Drugs and Delivery Devices Market Size Forecast by Delivery Device
16.14.1 Reusable Pens
16.14.2 Pens
16.14.3 Syringes
16.14.4 Safety Pen Needles
16.14.5 Pen Needles
16.14.6 Standard Pen Needles
16.14.7 Disposable Pens
16.15 Basis Point Share (BPS) Analysis by Delivery Device
16.16 Absolute $ Opportunity Assessment by Delivery Device
16.17 Market Attractiveness Analysis by Delivery Device
16.18 Middle East & Africa (MEA) Human Insulin Drugs and Delivery Devices Market Size Forecast by Product (Human Insulin
16.18.1 Human Insulin HI
16.19 Basis Point Share (BPS) Analysis by Product (Human Insulin
16.20 Absolute $ Opportunity Assessment by Product (Human Insulin
16.21 Market Attractiveness Analysis by Product (Human Insulin
16.22 Middle East & Africa (MEA) Human Insulin Drugs and Delivery Devices Market Size Forecast by Application
16.22.1 Type II Diabetes
16.22.2 Type I Diabetes
16.23 Basis Point Share (BPS) Analysis by Application
16.24 Absolute $ Opportunity Assessment by Application
16.25 Market Attractiveness Analysis by Application
Chapter 17 Competition Landscape
17.1 Human Insulin Drugs and Delivery Devices Market: Competitive Dashboard
17.2 Global Human Insulin Drugs and Delivery Devices Market: Market Share Analysis, 2019
17.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
17.3.1 Sanofi
17.3.2 AstraZeneca
17.3.3 WOCKHARDT
17.3.4 Johnson & Johnson Services Inc.
17.3.5 B. Braun Melsungen AG
17.3.6 Eli Lilly and Company
17.3.7 Novartis AG
17.3.8 Biocon
17.3.9 BD
17.3.10 Novo Nordisk A/S
17.3.11 CeQur SA
17.3.12 Takeda Pharmaceutical Company Limited
17.3.13 Ypsomed
17.3.14 Merck & Co. Inc.
17.3.15 BoehringerIngelheim International GmbH
17.3.16 Bayer AG
17.3.17 AlbireoPharma Inc.
17.3.18 Julphar
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Human Insulin Drugs and Delivery Devices Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Human Insulin Drugs and Delivery Devices Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Human Insulin Drugs and Delivery Devices Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Human Insulin Drugs and Delivery Devices Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Human Insulin Drugs and Delivery Devices Market Size & Forecast, 2018-2028
4.5.1 Human Insulin Drugs and Delivery Devices Market Size and Y-o-Y Growth
4.5.2 Human Insulin Drugs and Delivery Devices Market Absolute $ Opportunity
Chapter 5 Global Human Insulin Drugs and Delivery Devices Market Analysis and Forecast by Drug
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Drug
5.1.2 Basis Point Share (BPS) Analysis by Drug
5.1.3 Absolute $ Opportunity Assessment by Drug
5.2 Human Insulin Drugs and Delivery Devices Market Size Forecast by Drug
5.2.1 Insulin Analogs & Biosimilar
5.2.2 Premixed Biologics
5.2.3 Premixed Biosimilar
5.2.4 Short-Acting Biologics
5.2.5 Long-Acting Biosimilar
5.2.6 Human Insulin Biologics
5.2.7 Rapid-Acting Biosimilar
5.2.8 Intermediate-Acting Biologics
5.3 Market Attractiveness Analysis by Drug
Chapter 6 Global Human Insulin Drugs and Delivery Devices Market Analysis and Forecast by Human Insulin
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Human Insulin
6.1.2 Basis Point Share (BPS) Analysis by Human Insulin
6.1.3 Absolute $ Opportunity Assessment by Human Insulin
6.2 Human Insulin Drugs and Delivery Devices Market Size Forecast by Human Insulin
6.2.1 HI
6.3 Market Attractiveness Analysis by Human Insulin
Chapter 7 Global Human Insulin Drugs and Delivery Devices Market Analysis and Forecast by Delivery Device
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Delivery Device
7.1.2 Basis Point Share (BPS) Analysis by Delivery Device
7.1.3 Absolute $ Opportunity Assessment by Delivery Device
7.2 Human Insulin Drugs and Delivery Devices Market Size Forecast by Delivery Device
7.2.1 Reusable Pens
7.2.2 Pens
7.2.3 Syringes
7.2.4 Safety Pen Needles
7.2.5 Pen Needles
7.2.6 Standard Pen Needles
7.2.7 Disposable Pens
7.3 Market Attractiveness Analysis by Delivery Device
Chapter 8 Global Human Insulin Drugs and Delivery Devices Market Analysis and Forecast by Product (Human Insulin
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Product (Human Insulin
8.1.2 Basis Point Share (BPS) Analysis by Product (Human Insulin
8.1.3 Absolute $ Opportunity Assessment by Product (Human Insulin
8.2 Human Insulin Drugs and Delivery Devices Market Size Forecast by Product (Human Insulin
8.2.1 Human Insulin HI
8.3 Market Attractiveness Analysis by Product (Human Insulin
Chapter 9 Global Human Insulin Drugs and Delivery Devices Market Analysis and Forecast by Application
9.1 Introduction
9.1.1 Key Market Trends & Growth Opportunities by Application
9.1.2 Basis Point Share (BPS) Analysis by Application
9.1.3 Absolute $ Opportunity Assessment by Application
9.2 Human Insulin Drugs and Delivery Devices Market Size Forecast by Application
9.2.1 Type II Diabetes
9.2.2 Type I Diabetes
9.3 Market Attractiveness Analysis by Application
Chapter 10 Global Human Insulin Drugs and Delivery Devices Market Analysis and Forecast by Region
10.1 Introduction
10.1.1 Key Market Trends & Growth Opportunities by Region
10.1.2 Basis Point Share (BPS) Analysis by Region
10.1.3 Absolute $ Opportunity Assessment by Region
10.2 Human Insulin Drugs and Delivery Devices Market Size Forecast by Region
10.2.1 North America
10.2.2 Europe
10.2.3 Asia Pacific
10.2.4 Latin America
10.2.5 Middle East & Africa (MEA)
10.3 Market Attractiveness Analysis by Region
Chapter 11 Coronavirus Disease (COVID-19) Impact
11.1 Introduction
11.2 Current & Future Impact Analysis
11.3 Economic Impact Analysis
11.4 Government Policies
11.5 Investment Scenario
Chapter 12 North America Human Insulin Drugs and Delivery Devices Analysis and Forecast
12.1 Introduction
12.2 North America Human Insulin Drugs and Delivery Devices Market Size Forecast by Country
12.2.1 U.S.
12.2.2 Canada
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 North America Human Insulin Drugs and Delivery Devices Market Size Forecast by Drug
12.6.1 Insulin Analogs & Biosimilar
12.6.2 Premixed Biologics
12.6.3 Premixed Biosimilar
12.6.4 Short-Acting Biologics
12.6.5 Long-Acting Biosimilar
12.6.6 Human Insulin Biologics
12.6.7 Rapid-Acting Biosimilar
12.6.8 Intermediate-Acting Biologics
12.7 Basis Point Share (BPS) Analysis by Drug
12.8 Absolute $ Opportunity Assessment by Drug
12.9 Market Attractiveness Analysis by Drug
12.10 North America Human Insulin Drugs and Delivery Devices Market Size Forecast by Human Insulin
12.10.1 HI
12.11 Basis Point Share (BPS) Analysis by Human Insulin
12.12 Absolute $ Opportunity Assessment by Human Insulin
12.13 Market Attractiveness Analysis by Human Insulin
12.14 North America Human Insulin Drugs and Delivery Devices Market Size Forecast by Delivery Device
12.14.1 Reusable Pens
12.14.2 Pens
12.14.3 Syringes
12.14.4 Safety Pen Needles
12.14.5 Pen Needles
12.14.6 Standard Pen Needles
12.14.7 Disposable Pens
12.15 Basis Point Share (BPS) Analysis by Delivery Device
12.16 Absolute $ Opportunity Assessment by Delivery Device
12.17 Market Attractiveness Analysis by Delivery Device
12.18 North America Human Insulin Drugs and Delivery Devices Market Size Forecast by Product (Human Insulin
12.18.1 Human Insulin HI
12.19 Basis Point Share (BPS) Analysis by Product (Human Insulin
12.20 Absolute $ Opportunity Assessment by Product (Human Insulin
12.21 Market Attractiveness Analysis by Product (Human Insulin
12.22 North America Human Insulin Drugs and Delivery Devices Market Size Forecast by Application
12.22.1 Type II Diabetes
12.22.2 Type I Diabetes
12.23 Basis Point Share (BPS) Analysis by Application
12.24 Absolute $ Opportunity Assessment by Application
12.25 Market Attractiveness Analysis by Application
Chapter 13 Europe Human Insulin Drugs and Delivery Devices Analysis and Forecast
13.1 Introduction
13.2 Europe Human Insulin Drugs and Delivery Devices Market Size Forecast by Country
13.2.1 Germany
13.2.2 France
13.2.3 Italy
13.2.4 U.K.
13.2.5 Spain
13.2.6 Russia
13.2.7 Rest of Europe
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Europe Human Insulin Drugs and Delivery Devices Market Size Forecast by Drug
13.6.1 Insulin Analogs & Biosimilar
13.6.2 Premixed Biologics
13.6.3 Premixed Biosimilar
13.6.4 Short-Acting Biologics
13.6.5 Long-Acting Biosimilar
13.6.6 Human Insulin Biologics
13.6.7 Rapid-Acting Biosimilar
13.6.8 Intermediate-Acting Biologics
13.7 Basis Point Share (BPS) Analysis by Drug
13.8 Absolute $ Opportunity Assessment by Drug
13.9 Market Attractiveness Analysis by Drug
13.10 Europe Human Insulin Drugs and Delivery Devices Market Size Forecast by Human Insulin
13.10.1 HI
13.11 Basis Point Share (BPS) Analysis by Human Insulin
13.12 Absolute $ Opportunity Assessment by Human Insulin
13.13 Market Attractiveness Analysis by Human Insulin
13.14 Europe Human Insulin Drugs and Delivery Devices Market Size Forecast by Delivery Device
13.14.1 Reusable Pens
13.14.2 Pens
13.14.3 Syringes
13.14.4 Safety Pen Needles
13.14.5 Pen Needles
13.14.6 Standard Pen Needles
13.14.7 Disposable Pens
13.15 Basis Point Share (BPS) Analysis by Delivery Device
13.16 Absolute $ Opportunity Assessment by Delivery Device
13.17 Market Attractiveness Analysis by Delivery Device
13.18 Europe Human Insulin Drugs and Delivery Devices Market Size Forecast by Product (Human Insulin
13.18.1 Human Insulin HI
13.19 Basis Point Share (BPS) Analysis by Product (Human Insulin
13.20 Absolute $ Opportunity Assessment by Product (Human Insulin
13.21 Market Attractiveness Analysis by Product (Human Insulin
13.22 Europe Human Insulin Drugs and Delivery Devices Market Size Forecast by Application
13.22.1 Type II Diabetes
13.22.2 Type I Diabetes
13.23 Basis Point Share (BPS) Analysis by Application
13.24 Absolute $ Opportunity Assessment by Application
13.25 Market Attractiveness Analysis by Application
Chapter 14 Asia Pacific Human Insulin Drugs and Delivery Devices Analysis and Forecast
14.1 Introduction
14.2 Asia Pacific Human Insulin Drugs and Delivery Devices Market Size Forecast by Country
14.2.1 China
14.2.2 Japan
14.2.3 South Korea
14.2.4 India
14.2.5 Australia
14.2.6 South East Asia (SEA)
14.2.7 Rest of Asia Pacific (APAC)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Asia Pacific Human Insulin Drugs and Delivery Devices Market Size Forecast by Drug
14.6.1 Insulin Analogs & Biosimilar
14.6.2 Premixed Biologics
14.6.3 Premixed Biosimilar
14.6.4 Short-Acting Biologics
14.6.5 Long-Acting Biosimilar
14.6.6 Human Insulin Biologics
14.6.7 Rapid-Acting Biosimilar
14.6.8 Intermediate-Acting Biologics
14.7 Basis Point Share (BPS) Analysis by Drug
14.8 Absolute $ Opportunity Assessment by Drug
14.9 Market Attractiveness Analysis by Drug
14.10 Asia Pacific Human Insulin Drugs and Delivery Devices Market Size Forecast by Human Insulin
14.10.1 HI
14.11 Basis Point Share (BPS) Analysis by Human Insulin
14.12 Absolute $ Opportunity Assessment by Human Insulin
14.13 Market Attractiveness Analysis by Human Insulin
14.14 Asia Pacific Human Insulin Drugs and Delivery Devices Market Size Forecast by Delivery Device
14.14.1 Reusable Pens
14.14.2 Pens
14.14.3 Syringes
14.14.4 Safety Pen Needles
14.14.5 Pen Needles
14.14.6 Standard Pen Needles
14.14.7 Disposable Pens
14.15 Basis Point Share (BPS) Analysis by Delivery Device
14.16 Absolute $ Opportunity Assessment by Delivery Device
14.17 Market Attractiveness Analysis by Delivery Device
14.18 Asia Pacific Human Insulin Drugs and Delivery Devices Market Size Forecast by Product (Human Insulin
14.18.1 Human Insulin HI
14.19 Basis Point Share (BPS) Analysis by Product (Human Insulin
14.20 Absolute $ Opportunity Assessment by Product (Human Insulin
14.21 Market Attractiveness Analysis by Product (Human Insulin
14.22 Asia Pacific Human Insulin Drugs and Delivery Devices Market Size Forecast by Application
14.22.1 Type II Diabetes
14.22.2 Type I Diabetes
14.23 Basis Point Share (BPS) Analysis by Application
14.24 Absolute $ Opportunity Assessment by Application
14.25 Market Attractiveness Analysis by Application
Chapter 15 Latin America Human Insulin Drugs and Delivery Devices Analysis and Forecast
15.1 Introduction
15.2 Latin America Human Insulin Drugs and Delivery Devices Market Size Forecast by Country
15.2.1 Brazil
15.2.2 Mexico
15.2.3 Rest of Latin America (LATAM)
15.3 Basis Point Share (BPS) Analysis by Country
15.4 Absolute $ Opportunity Assessment by Country
15.5 Market Attractiveness Analysis by Country
15.6 Latin America Human Insulin Drugs and Delivery Devices Market Size Forecast by Drug
15.6.1 Insulin Analogs & Biosimilar
15.6.2 Premixed Biologics
15.6.3 Premixed Biosimilar
15.6.4 Short-Acting Biologics
15.6.5 Long-Acting Biosimilar
15.6.6 Human Insulin Biologics
15.6.7 Rapid-Acting Biosimilar
15.6.8 Intermediate-Acting Biologics
15.7 Basis Point Share (BPS) Analysis by Drug
15.8 Absolute $ Opportunity Assessment by Drug
15.9 Market Attractiveness Analysis by Drug
15.10 Latin America Human Insulin Drugs and Delivery Devices Market Size Forecast by Human Insulin
15.10.1 HI
15.11 Basis Point Share (BPS) Analysis by Human Insulin
15.12 Absolute $ Opportunity Assessment by Human Insulin
15.13 Market Attractiveness Analysis by Human Insulin
15.14 Latin America Human Insulin Drugs and Delivery Devices Market Size Forecast by Delivery Device
15.14.1 Reusable Pens
15.14.2 Pens
15.14.3 Syringes
15.14.4 Safety Pen Needles
15.14.5 Pen Needles
15.14.6 Standard Pen Needles
15.14.7 Disposable Pens
15.15 Basis Point Share (BPS) Analysis by Delivery Device
15.16 Absolute $ Opportunity Assessment by Delivery Device
15.17 Market Attractiveness Analysis by Delivery Device
15.18 Latin America Human Insulin Drugs and Delivery Devices Market Size Forecast by Product (Human Insulin
15.18.1 Human Insulin HI
15.19 Basis Point Share (BPS) Analysis by Product (Human Insulin
15.20 Absolute $ Opportunity Assessment by Product (Human Insulin
15.21 Market Attractiveness Analysis by Product (Human Insulin
15.22 Latin America Human Insulin Drugs and Delivery Devices Market Size Forecast by Application
15.22.1 Type II Diabetes
15.22.2 Type I Diabetes
15.23 Basis Point Share (BPS) Analysis by Application
15.24 Absolute $ Opportunity Assessment by Application
15.25 Market Attractiveness Analysis by Application
Chapter 16 Middle East & Africa (MEA) Human Insulin Drugs and Delivery Devices Analysis and Forecast
16.1 Introduction
16.2 Middle East & Africa (MEA) Human Insulin Drugs and Delivery Devices Market Size Forecast by Country
16.2.1 Saudi Arabia
16.2.2 South Africa
16.2.3 UAE
16.2.4 Rest of Middle East & Africa (MEA)
16.3 Basis Point Share (BPS) Analysis by Country
16.4 Absolute $ Opportunity Assessment by Country
16.5 Market Attractiveness Analysis by Country
16.6 Middle East & Africa (MEA) Human Insulin Drugs and Delivery Devices Market Size Forecast by Drug
16.6.1 Insulin Analogs & Biosimilar
16.6.2 Premixed Biologics
16.6.3 Premixed Biosimilar
16.6.4 Short-Acting Biologics
16.6.5 Long-Acting Biosimilar
16.6.6 Human Insulin Biologics
16.6.7 Rapid-Acting Biosimilar
16.6.8 Intermediate-Acting Biologics
16.7 Basis Point Share (BPS) Analysis by Drug
16.8 Absolute $ Opportunity Assessment by Drug
16.9 Market Attractiveness Analysis by Drug
16.10 Middle East & Africa (MEA) Human Insulin Drugs and Delivery Devices Market Size Forecast by Human Insulin
16.10.1 HI
16.11 Basis Point Share (BPS) Analysis by Human Insulin
16.12 Absolute $ Opportunity Assessment by Human Insulin
16.13 Market Attractiveness Analysis by Human Insulin
16.14 Middle East & Africa (MEA) Human Insulin Drugs and Delivery Devices Market Size Forecast by Delivery Device
16.14.1 Reusable Pens
16.14.2 Pens
16.14.3 Syringes
16.14.4 Safety Pen Needles
16.14.5 Pen Needles
16.14.6 Standard Pen Needles
16.14.7 Disposable Pens
16.15 Basis Point Share (BPS) Analysis by Delivery Device
16.16 Absolute $ Opportunity Assessment by Delivery Device
16.17 Market Attractiveness Analysis by Delivery Device
16.18 Middle East & Africa (MEA) Human Insulin Drugs and Delivery Devices Market Size Forecast by Product (Human Insulin
16.18.1 Human Insulin HI
16.19 Basis Point Share (BPS) Analysis by Product (Human Insulin
16.20 Absolute $ Opportunity Assessment by Product (Human Insulin
16.21 Market Attractiveness Analysis by Product (Human Insulin
16.22 Middle East & Africa (MEA) Human Insulin Drugs and Delivery Devices Market Size Forecast by Application
16.22.1 Type II Diabetes
16.22.2 Type I Diabetes
16.23 Basis Point Share (BPS) Analysis by Application
16.24 Absolute $ Opportunity Assessment by Application
16.25 Market Attractiveness Analysis by Application
Chapter 17 Competition Landscape
17.1 Human Insulin Drugs and Delivery Devices Market: Competitive Dashboard
17.2 Global Human Insulin Drugs and Delivery Devices Market: Market Share Analysis, 2019
17.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
17.3.1 Sanofi
17.3.2 AstraZeneca
17.3.3 WOCKHARDT
17.3.4 Johnson & Johnson Services Inc.
17.3.5 B. Braun Melsungen AG
17.3.6 Eli Lilly and Company
17.3.7 Novartis AG
17.3.8 Biocon
17.3.9 BD
17.3.10 Novo Nordisk A/S
17.3.11 CeQur SA
17.3.12 Takeda Pharmaceutical Company Limited
17.3.13 Ypsomed
17.3.14 Merck & Co. Inc.
17.3.15 BoehringerIngelheim International GmbH
17.3.16 Bayer AG
17.3.17 AlbireoPharma Inc.
17.3.18 Julphar
Segments Covered in the Report
The global Human Insulin Drugs and Delivery Devices market has been segmented based on
By Drug
The global Human Insulin Drugs and Delivery Devices market has been segmented based on
By Drug
- Insulin Analogs & Biosimilar
- Premixed Biologics
- Premixed Biosimilar
- Short-Acting Biologics
- Long-Acting Biosimilar
- Human Insulin Biologics
- Rapid-Acting Biosimilar
- Intermediate-Acting Biologics
- HI
- Reusable Pens
- Pens
- Syringes
- Safety Pen Needles
- Pen Needles
- Standard Pen Needles
- Disposable Pens
- Human Insulin HI
- Type II Diabetes
- Type I Diabetes
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Sanofi
- AstraZeneca
- WOCKHARDT
- Johnson & Johnson Services Inc.
- B. Braun Melsungen AG
- Eli Lilly and Company
- Novartis AG
- Biocon
- BD
- Novo Nordisk A/S
- CeQur SA
- Takeda Pharmaceutical Company Limited
- Ypsomed
- Merck & Co. Inc.
- BoehringerIngelheim International GmbH
- Bayer AG
- AlbireoPharma Inc.
- Julphar
Our Clients
Related Reports
Some other reports from this category!
